Table 1.

Baseline characteristics of all enrolled patients

CharacteristicsCiforadenant(n = 33)Ciforadenant + atezolizumab(n = 35)
Age, years [median (range)]60 (47–76)65 (44–77)
Gender, male n (%)25 (75.8)28 (80)
Sites of disease, n (%)
 Lung22 (66.7%)27 (77.1%)
 Lymph node19 (57.6%)21 (60%)
 Bone16 (48.5%)15 (42.9%)
 Liver10 (30.3)9 (25.7%)
Number of prior therapies
 Median, range3 (1, 5)3 (1, 5)
Prior IO, number of subjects, n (%)24 (72.7)25 (71.4)
Months since prior IO
 Median, range3.1 (1.2, 70.4)1.7 (0.9, 23.6)
PD-L1 IHC status
 ≥5% PD-L1+ on TC or IC, n (%)2/27 (7.4%)3/31 (9.7%)
Prior anticancer therapy, n (%)
 TKI27 (81.8)30 (85.7)
 mTOR9 (27.3)11 (31.4)
 Anti–PD-123 (69.7)25 (71.4)
 Anti-VEGF, bevacizumab6 (18.2)4 (11.4)
 IL27 (21.2)9 (25.7)

Abbreviations: IO, immunotherapy; TC, tumor cells; IC, immune cells.